SUMMARY

JS003 Competitive Landscape in China

Generic 
Name

Brand 
Name

Company

China
Filing
Status

Key
MOA

Proposed 
Indications

Retail 
Price
(RMB)

IND

NDA 

Approved

Submitted 

Time

Time

Category

Atezolizumab  Tecentriq  

Roche   

Phase III

Anti-PD-L1

Durvalumab  

Imfinzi  

AstraZeneca  

Phase III

Anti-PD-L1

HNSCC, HCC, NSCLC, 
TNBC, mCRPC, 
RCC,UC, SCLC

NSCLC, Liver cancer, 
 
UC

N.A. 

2015.11  

N.A. 

N.A. 

2016.08  

N.A. 

Imported therapeutic 

biologics

Imported therapeutic 

biologics

Avelumab   Bavencio  

Merck KGaA,

Pfizer

 

Phase III

KN035 

Alphamab, 3DMed  

Phase III

 

 

Anti-PD-L1

HNSCC
 

N.A. 

2016.11  

N.A. 

Imported therapeutic 

biologics

Anti-PD-L1

Biliary tract cancer
 

N.A. 

2017.01  

N.A. 

Therapeutic 

biologics category 1

 

 

 

 

 

Therapeutic 

biologics category 1

Therapeutic 

biologics category 1

Therapeutic 

biologics category 1

CS1001
 

Cstone 

Phase III

Anti-PD-L1

NSCLC
 

N.A. 

2017.07  

N.A. 

KL-A167
 

Kelun Group 

Phase II

Anti-PD-L1

TQB2450 

Chiatiai Tianqing, CBT 

Pharma

Phase II

Anti-PD-L1

Classic  Hodgkin 
lymphoma
 

Advanced malignant 
 
tumor 

N.A. 

2017.09  

N.A. 

Therapeutic 

biologics category 1

 

N.A. 

2017.11  

N.A. 

ZKAB001 

Zhaoke Pharma  

Phase I/II

Anti-PD-L1

Osteosarcoma
 

N.A. 

2018.01  

N.A. 

JS003 

Junshi 

IND

approval 

 

Anti-PD-L1

Solid tumor
 

N.A. 

2018.08  

N.A. 

Therapeutic 

biologics category 1

 

Notes:

(1)

HNSCC: Head and neck squamous cell carcinoma; HCC: Hepatocellular carcinoma; TNBC: Triple-negative
breast cancer; mCRPC: metastatic castrate-resistant prostate cancer; RCC: Renal cell carcinoma; UC:
Urothelium carcinoma; SCLC: Small cell lung cancer.

(2)

All of the products are not included in the NRDL or PRDL.

– 6 –

